What is the current Price Target for the Apogee Therapeutics stock?

The average Apogee Therapeutics target price is $137.70. This is 1.95% higher than the current stock price. The highest price target is 5.03%, the lowest is -2.04%. 14 Analysts have issued a price target Apogee Therapeutics 2027 .

How high will the Apogee Therapeutics stock rise?

No reliable answer can be given as to how high the Apogee Therapeutics stock will rise. The performance of stocks, including the Apogee Therapeutics stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Apogee Therapeutics stock today?

The performance of Apogee Therapeutics stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Apogee Therapeutics stock fall?

The decline in Apogee Therapeutics stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Apogee Therapeutics Forecast, price target & analysts

$135.07

0.00%

NYSE, Mon, Sep 14 2026.

ISIN

US03770N1019

Symbol

APGE

Reports

Quarter | Annual

Index

S&P SmallCap 600

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Analysts Charts Ownership News Strategies

Apogee Therapeutics Target price 2026 - Analyst rating & recommendation

Apogee Therapeutics Classifications & Recommendation

Buy

29%

Hold

71%

Apogee Therapeutics Price Target

Target Price	$137.70
Price	$135.07
Potential	1.95% register free of charge
Number of Estimates	14

	14 Analysts have issued a price target Apogee Therapeutics 2027 . The average Apogee Therapeutics target price is $137.70. This is 1.95% register free of charge higher than the current stock price. The highest price target is $141.87 5.03% register free of charge , the lowest is $132.31 2.04% register free of charge .
	A rating was issued by 21 analysts: 6 Analysts recommend Apogee Therapeutics to buy, 15 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Apogee Therapeutics stock has an average upside potential 2027 of 1.95% register free of charge . Most analysts recommend the Apogee Therapeutics stock at Hold.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '25	2026 Estimates
Earnings Per Share $	-4.22	-4.64
	27.88%	9.95%
P/E		negative

18 Analysts have issued a Apogee Therapeutics forecast for earnings per share. The average Apogee Therapeutics EPS is

unlock

. This is

unlock

than earnings per share in the financial year 2025. The highest EPS forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics and future valuations:

2025	$-4.22	27.88%
2026	$-4.64 9.95% unlock
2027	$-5.71 23.06% unlock
2028	$-6.66 16.64% unlock
2029	$-5.58 16.22% unlock
2030	$-2.20 60.57% unlock
2031	$3.41 255.00% unlock
2032	$14.83 334.90% unlock
2033	$22.06 48.75% unlock

Current	-34.63	284.92%
2026	-29.10 15.98% unlock
2027	-23.67 18.66% unlock
2028	-20.29 14.28% unlock
2029	-24.21 19.32% unlock
2030	-61.37 153.49% unlock
2031	39.65 164.61% unlock
2032	9.11 77.02% unlock
2033	6.12 32.82% unlock

Apogee Therapeutics...

Current Apogee Therapeutics Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Truist Securities	Locked ➜ Locked	Locked	Aug 13 2026
BTIG	Locked ➜ Locked	Locked	Aug 12 2026
Stifel	Locked ➜ Locked	Locked	Jun 24 2026
TD Cowen	Locked ➜ Locked	Locked	Jun 24 2026
Mizuho	Locked ➜ Locked	Locked	Jun 24 2026
Guggenheim	Locked ➜ Locked	Locked	Jun 24 2026
Deutsche Bank	Locked ➜ Locked	Locked	Jun 23 2026

Analyst Rating	Date
Locked Truist Securities: Locked ➜ Locked	Aug 13 2026
Locked BTIG: Locked ➜ Locked	Aug 12 2026
Locked Stifel: Locked ➜ Locked	Jun 24 2026
Locked TD Cowen: Locked ➜ Locked	Jun 24 2026
Locked Mizuho: Locked ➜ Locked	Jun 24 2026
Locked Guggenheim: Locked ➜ Locked	Jun 24 2026
Locked Deutsche Bank: Locked ➜ Locked	Jun 23 2026

Discover more stocks with a high price target

NIO ADR 101.75%

Alibaba Group Holding Ltd 70.15%

Tencent Holdings Ltd. 56.53%

Uber Technologies 48.83%

Siemens Energy 47.15%

BYD 47.08%

Adidas 46.64%

Deutsche Telekom 38.45%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now